FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Patricia Ball

Research Profile

Disorders

Procedures

Activities & Behaviors

Chemicals & Drugs

Concepts & Ideas

Physiology

Attention

Co-author Network

Publications

TOP 3
Kimberly R Warren; Jared Linthicum; Fang Liu; Robert P McMahon; M Patricia Ball; Robert W Buchanan; Robert R Conley; Stephanie Feldman; David A Gorelick; Marilyn A Huestis; Deanna L Kelly
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Daniel C Javitt; Richard S E Keefe; Robert Kern; David Kimhy; Jeffrey Lieberman; Joseph P McEvoy; Robert P McMahon; Karen S Nolan; James Robinson; Larry J Seidman; M Patricia Ball; Deanna S Barch; Robert W Buchanan; John G Csernansky; Donald C Goff; James M Gold; Michael F Green; Fred Jarskog; Stephen R Marder
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Elaine Weiner; M Patricia Ball; Alison S Buchholz; A Eden Evins; James M Gold; Robert P McMahon; Robert W Buchanan
Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Patricia Ball (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kimberly R Warren; Jared Linthicum; Fang Liu; Robert P McMahon; M Patricia Ball; Robert W Buchanan; Robert R Conley; Stephanie Feldman; David A Gorelick; Marilyn A Huestis; Deanna L Kelly
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Journal of clinical psychopharmacology 2013;33(1):118-20.
2012: Daniel C Javitt; Richard S E Keefe; Robert Kern; David Kimhy; Jeffrey Lieberman; Joseph P McEvoy; Robert P McMahon; Karen S Nolan; James Robinson; Larry J Seidman; M Patricia Ball; Deanna S Barch; Robert W Buchanan; John G Csernansky; Donald C Goff; James M Gold; Michael F Green; Fred Jarskog; Stephen R Marder
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Schizophrenia research 2012;136(1-3):25-31.
2012: Elaine Weiner; M Patricia Ball; Alison S Buchholz; A Eden Evins; James M Gold; Robert P McMahon; Robert W Buchanan
Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis.
The Journal of clinical psychiatry 2012;73(1):95-102.
2011: Kimberly R Warren; M Patricia Ball; Stephanie Feldman; Fang Liu; Robert P McMahon; Deanna L Kelly
Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia.
Biological research for nursing 2011;13(4):383-90.
2011: M Patricia Ball; Kimberly R Warren; Stephanie Feldman; Robert P McMahon; Deanna L Kelly; Robert W Buchanan
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
Clinical schizophrenia & related psychoses 2011;5(1):17-25.
2011: Robert W Buchanan; Richard S E Keefe; Jeffrey A Lieberman; Deanna M Barch; John G Csernansky; Donald C Goff; James M Gold; Michael F Green; L Fredrik Jarskog; Daniel C Javitt; David Kimhy; Michael S Kraus; Joseph P McEvoy; Raquelle I Mesholam-Gately; Larry J Seidman; M Patricia Ball; Robert P McMahon; Robert S Kern; James Robinson; Stephen R Marder
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
Biological psychiatry 2011;69(5):442-9.
2011: Monica C Mann-Wrobel; Melanie E Bennett; Elaine Weiner; Robert W Buchanan; M Patricia Ball
Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program.
Schizophrenia research 2011;126(1-3):277-83.
2011: Deanna L Kelly; David A Gorelick; Robert R Conley; Douglas L Boggs; Jared Linthicum; Fang Liu; Stephanie Feldman; M Patricia Ball; Heidi Wehring; Robert P McMahon; Marilyn A Huestis; STEPHEN HEISHMAN; Kimberly R Warren; Robert W Buchanan
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Journal of clinical psychopharmacology 2011;31(1):86-91.
2010: Elaine Weiner; Robert R Conley; M Patricia Ball; Stephanie Feldman; James M Gold; Deanna L Kelly; Ikwunga Wonodi; Robert P McMahon; Robert W Buchanan
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2010;35(11):2274-83.
2009: Deanna L Kelly; Elaine Weiner; M Patricia Ball; Robert P McMahon; William T Carpenter; Robert W Buchanan
Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.
Journal of psychopharmacology (Oxford, England) 2009;23(4):436-41.
2009: Deanna L Kelly; Robert W Buchanan; Douglas L Boggs; Robert P McMahon; Dwight Dickinson; Matthew Nelson; James M Gold; M Patricia Ball; Stephanie Feldman; Fang Liu; Robert R Conley
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.
The Journal of clinical psychiatry 2009;70(4):518-25.
2009: Robert R Conley; Douglas L Boggs; Deanna L Kelly; Robert P McMahon; Dwight Dickinson; Stephanie Feldman; M Patricia Ball; Robert W Buchanan
The effects of galantamine on psychopathology in chronic stable schizophrenia.
Clinical neuropharmacology 2009;32(2):69-74.
2008: Robert Freedman; Ann Olincy; Robert W Buchanan; Josette G Harris; James M Gold; Lynn Johnson; Diana Allensworth; Alejandrina Guzman-Bonilla; Bettye Clement; M Patricia Ball; Jay Kutnick; Vicki Pender; Laura F Martin; Karen E Stevens; Brandie D Wagner; Gary O Zerbe; Ferenc Soti; William R Kem
Initial phase 2 trial of a nicotinic agonist in schizophrenia.
The American journal of psychiatry 2008;165(8):1040-7.
2008: Robert W Buchanan; Robert R Conley; Dwight Dickinson; M Patricia Ball; Stephanie Feldman; James M Gold; Robert P McMahon
Galantamine for the treatment of cognitive impairments in people with schizophrenia.
The American journal of psychiatry 2008;165(1):82-9.
2005: Robert W Buchanan; M Patricia Ball; Elaine Weiner; Brian Kirkpatrick; James M Gold; Robert P McMahon; William T Carpenter
Olanzapine treatment of residual positive and negative symptoms.
The American journal of psychiatry 2005;162(1):124-9.
2003: Scott P Baymiller; M Patricia Ball; Robert P McMahon; Robert W Buchanan
Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment.
Schizophrenia research 2003;59(1):49-57.
2002: Scott P Baymiller; M Patricia Ball; Robert P McMahon; Robert W Buchanan
Weight and blood pressure change during clozapine treatment.
Clinical neuropharmacology 2002;25(4):202-6.
2001: M Patricia Ball; V B Coons; Robert W Buchanan
A program for treating olanzapine-related weight gain.
Psychiatric services (Washington, D.C.) 2001;52(7):967-9.
2001: Elaine Weiner; M Patricia Ball; Ann Summerfelt; James M Gold; Robert W Buchanan
Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia.
The American journal of psychiatry 2001;158(4):635-7.
1998: Robert W Buchanan; Alan Breier; Brian Kirkpatrick; M Patricia Ball; William T Carpenter
Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.
The American journal of psychiatry 1998;155(6):751-60.
1996: Robert W Buchanan; Brian Kirkpatrick; N Bryant; M Patricia Ball; Alan Breier
Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.
The American journal of psychiatry 1996;153(12):1625-7.